Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
S-8
Registration of securities for employees
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
6 Mar 24
8-K
Termination of a Material Definitive Agreement
2 Feb 24
8-K
Other Events
8 Jan 24
8-K
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
29 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
9 Nov 23
8-K
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
26 Oct 23
8-K
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
18 Oct 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Generation Bio Reports Second Quarter 2023 Financial Results
2 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results
10 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
10 Apr 23
8-K
Departure of Directors or Certain Officers
5 Apr 23
8-K
Amendments to Articles of Incorporation or Bylaws
4 Apr 23
8-K
Entry into a Material Definitive Agreement
23 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23
S-8
Registration of securities for employees
12 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
3 Nov 22
8-K
Departure of Directors or Certain Officers
20 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results
4 Aug 22
8-K
Departure of Directors or Certain Officers
18 Jul 22
8-K
Generation Bio Announces Update to Its GMP Manufacturing Strategy
21 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
EFFECT
Notice of effectiveness
10 May 22
10-Q
2022 Q1
Quarterly report
5 May 22
8-K
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results
5 May 22
Latest ownership filings
4
Matthew Stanton
17 Apr 24
4
Phillip Samayoa
17 Apr 24
4
Antoinette Paone
17 Apr 24
4
Matthew Norkunas
17 Apr 24
4
GEOFF MCDONOUGH
17 Apr 24
4
Yalonda Howze
17 Apr 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G/A
Atlas Venture Fund X, L.P.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Tracy Zimmermann
31 Jan 24
4
Douglas Kerr
31 Jan 24
4
Tracy Zimmermann
17 Jan 24
4
Douglas Kerr
17 Jan 24
4
Matthew Stanton
17 Jan 24
4
Matthew Norkunas
17 Jan 24
4
GEOFF MCDONOUGH
17 Jan 24
4
Phillip Samayoa
17 Jan 24
4
Antoinette Paone
17 Jan 24
SC 13G/A
BlackRock Inc.
8 Jan 24
4
Antoinette Paone
3 Jan 24
4
Matthew Stanton
3 Jan 24
4
Phillip Samayoa
3 Jan 24
4
Matthew Norkunas
3 Jan 24
4
GEOFF MCDONOUGH
3 Jan 24
4
Yalonda Howze
3 Jan 24
4
Dannielle Appelhans
11 Dec 23
SC 13G/A
FMR LLC
11 Dec 23
4
Dannielle Appelhans
6 Dec 23
4
Phillip Samayoa
5 Dec 23
4
Matthew Stanton
5 Dec 23
4
Matthew Norkunas
5 Dec 23
4
Anthony G. Quinn
5 Dec 23
4
Antoinette Paone
5 Dec 23
4
GEOFF MCDONOUGH
5 Dec 23
4
Charles A Rowland Jr
5 Dec 23
4
Yalonda Howze
5 Dec 23
4
Donald William Nicholson
5 Dec 23
4
Phillip Samayoa
17 Oct 23
4
Matthew Stanton
17 Oct 23